| Database ID | Agent | Target | Cancer Type | Detail |
| DB00676 | erlotinib, lapatinib plus trastuzumab, sorafenib, imatinib, dasatinib, vemurafenib, everolimus, abiraterone, letrozole, tamoxifen | NA | advanced solid tumors | view |
| DB00677 | RRx001 | Free radicals | advanced solid tumors | view |
| DB00678 | PF04605412 | integrin ¦Á5¦Â1 | advanced solid tumors | view |
| DB00679 | navitoclax | Bcl2like protein 2
Antiapoptotic protein BCLXL
Apoptosis regulator Bcl2 | advanced solid tumors | view |
| DB00680 | patritumab | Receptor proteintyrosine kinase erbB3 | advanced solid tumors | view |
| DB00681 | PNT2258 | mRNA of BCL2 | advanced solid tumors | view |
| DB00682 | imatinib mesylate | Abl
Plateletderived growth factor receptor
Mast/stem cell growth factor receptor | advanced solid tumors | view |
| DB00683 | Sorafenib and bevacizumab | NA | neuroendocrine tumour | view |
| DB00684 | sorafenib bortezomib | NA | advanced solid tumors | view |
| DB00685 | tremelimumab | cytotoxic Tlymphocyteassociated antigen 4 (CTLA4) | advanced solid tumors | view |
| DB00686 | BMS690514 | epidermal growth factor receptor (EGFR/HER1), HER2 and 4, and vascular endothelial growth factor receptors (VEGFRs)1 to 3 | advanced solid tumors | view |
| DB00687 | amuvatinib | mutant KIT, plateletderived growth factor receptor alpha (PDGFR¦Á), and Rad51 | advanced solid tumors | view |
| DB00688 | L19TNF | Tumour necrosis factor (TNF) | advanced solid tumors | view |
| DB00689 | lapatinib, sorafenib | NA | advanced solid tumors | view |
| DB00690 | AVE1642 | Type 1 insulinlike growth factor receptor | advanced solid tumors | view |